Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
The goal of CLL management is to maintain the best quality of life and treat only when patients become symptomatic from their disease. 7,8 Unlike other hematologic malignancies, CLL is a long-term, ...
Dr Suchitra Sundaram reflects on time limited venetoclax combinations, next generation non covalent BTK inhibitors, and novel ...
Lori A. Leslie, MD, and Hoshiyuki Iida, APN, offer closing thoughts on the future treatment landscape of chronic lymphocytic leukemia. Lori A. Leslie, MD: We’ve talked a lot about how this landscape ...
BeOne Medicines’ Novel BCL2 inhibitor, sonrotoclax, achieves first-in-world approval in R/R MCL and R/R CLL/SLL: San Carlos, California Thursday, January 8, 2026, 13:00 Hrs [IST ...
The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
“This study demonstrates that a PA intervention utilizing aerobic exercise can increase leisure time PA and decrease fatigue in older adult patients with CLL, and that these changes are correlated to ...
The FDA granted accelerated approval to lisocabtagene maraleucel (liso-cel, Breyanzi) for pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), drugmaker Bristol Myers ...
The narrative highlights the importance of creating intentional spaces of silence and mindfulness amidst the chaos of chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback